Larimar Therapeutics (LRMR) risk factors

100 risks, 11 new, 8 dropped, 17 reworded since the prior year. Cash of $136.9 million plus $107.6 million from a February 2026 offering funds operations into the second quarter of 2027. Net operating loss carryforwards increased from $198.2 million to $349.9 million. Regulatory risks center on the development and commercialization of lead candidate nomlabofusp for Friedreich's ataxia.

97 risks. Larimar has incurred substantial losses since inception with an accumulated deficit of $269.2 million as of December 31, 2024. The company relies entirely on the clinical success and regulatory approval of its single lead product candidate, nomlabofusp. Existing cash of $183.5 million is expected to fund operations into the second quarter of 2026.